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Pregnancy-associated breast cancers are driven
by differences in adipose stromal cells present
during lactation
Jessica McCready1,2,6, Lisa M Arendt1,2, Eugene Glover1,2, Vandana Iyer1,2, Jerrica L Briendel1,2, Stephen R Lyle3,
Stephen P Naber5, Daniel G Jay4 and Charlotte Kuperwasser1,2*
Abstract
Introduction: The prognosis of breast cancer is strongly influenced by the developmental stage of the breast when
the tumor is diagnosed. Pregnancy-associated breast cancers (PABCs), cancers diagnosed during pregnancy, lactation,
or in the first postpartum year, are typically found at an advanced stage, are more aggressive and have a poorer
prognosis. Although the systemic and microenvironmental changes that occur during post-partum involution have
been best recognized for their role in the pathogenesis of PABCs, epidemiological data indicate that PABCs diagnosed
during lactation have an overall poorer prognosis than those diagnosed during involution. Thus, the physiologic
and/or biological events during lactation may have a significant and unrecognized role in the pathobiology of PABCs.
Methods: Syngeneic in vivo mouse models of PABC were used to examine the effects of system and stromal factors
during pregnancy, lactation and involution on mammary tumorigenesis. Mammary adipose stromal cell (ASC)
populations were isolated from mammary glands and examined by using a combination of in vitro and in vivo
functional assays, gene expression analysis, and molecular and cellular assays. Specific findings were further
investigated by immunohistochemistry in mammary glands of mice as well as in functional studies using ASCs from
lactating mammary glands. Additional findings were further investigated using human clinical samples, human stromal
cells and using in vivo xenograft assays.
Results: ASCs present during lactation (ASC-Ls), but not during other mammary developmental stages, promote the
growth of carcinoma cells and angiogenesis. ASCs-Ls are distinguished by their elevated expression of cellular retinoic
acid binding protein-1 (crabp1), which regulates their ability to retain lipid. Human breast carcinoma-associated
fibroblasts (CAFs) exhibit traits of ASC-Ls and express crabp1. Inhibition of crabp1in CAFs or in ASC-Ls abolished their
tumor-promoting activity and also restored their ability to accumulate lipid.
Conclusions: These findings imply that (1) PABC is a complex disease, which likely has different etiologies when
diagnosed during different stages of pregnancy; (2) both systemic and local factors are important for the pathobiology
of PABCs; and (3) the stromal changes during lactation play a distinct and important role in the etiology and
pathogenesis of PABCs that differ from those during post-lactational involution.
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Introduction
The etiology and prognosis of breast cancer is complex
with many factors contributing to both the lifetime risk
of developing the disease and the aggressiveness of the
disease once it is diagnosed. For example, breast cancers
diagnosed in premenopausal women tend to be more ag-
gressive than those diagnosed in postmenopausal women
[1-3]. Likewise, pregnancy-associated breast cancers
(PABCs), those diagnosed during pregnancy, lactation,
or in the first postpartum year, are typically found at an
advanced stage, have a higher incidence of lymph node
metastases and are poorly differentiated [4-13].
Several hypotheses have been proposed to explain the
etiology and pathobiology of PABCs. One hypothesis
suggests that the elevated levels of circulating hormones
present during pregnancy act on cancer cells to increase
their biologic aggressiveness [4,13-15]. A second hypoth-
esis suggests that the hormonal changes present during
and following pregnancy increase vascularization and in-
flammatory cell recruitment, which together contribute to
the adverse outcomes associated with PABCs [4,13,16].
Experimental support for the latter model comes from
recent studies showing that implantation of cancer cells
into the mammary glands of mice undergoing involution
leads to accelerated tumor formation and metastasis
through increased inflammation, matrix remodeling and
angiogenesis [16-19]. Such experiments have emphasized
the importance of involution on PABCs despite the fact
that significant epidemiological data indicate that breast
cancers diagnosed during lactation exhibit the most ag-
gressive traits and an elevation in cause-specific death
[10,13,15,20,21]. This association could not be explained
by or adjusted for age, extent of disease or pregnancy
hormones. Thus, the physiologic and/or biological
events unique to lactation but not to other stages of
pregnancy may have a significant and unrecognized role
in the pathobiology of aggressive PABCs.
Lactation is a stage of mammary gland development
associated with epithelial terminal differentiation and
milk production. This stage is also associated with sig-
nificant changes to the vasculature, the adipose tissue
and the extracellular matrix [22,23]. During lactation,
adipocyte and stromal remodeling is recognized for its
importance in meeting the nutritional and metabolic de-
mands of the expanding epithelium as well as in provid-
ing paracrine endocrine functions that are necessary for
proper milk production [22,23]. Thus, it is highly plaus-
ible that these changes may be co-opted to meet the nu-
tritional and metabolic needs of an expanding carcinoma
leading to aggressive features; however, whether this is
the case and whether it plays a role in PABCs is unclear.
In this study, we sought to study mammary stromal
remodeling during development to examine its role in
PABCs. Using a well-defined in vivo model of mammary
gland development, we discovered that adipose tissue
stromal cells (ASCs) present in the mammary gland dur-
ing lactation provide novel insights into the phenotypic
and functional diversity of stromal cells in development
and reveal their importance in the pathogenesis of
PABCs.
Methods
Cell lines and tissue culture
The 4T1-12B cell line [24] was obtained from Dr. Gary
Sahagian (Tufts University), while the COMMA D cell
line [25] was obtained from Dr. Daniel Medina (Baylor Uni-
versity) and the SUM159 cell line was obtained from
Dr. Stephen Ethier (Kramanos Institute). NIH3T3 and 3T3-
L1 cells were purchased from ATCC (Manassas, Virginia,
USA). 4T1-12B, Comma D, NIH-3T3, and cells were
cultured in (D)MEM with 10% fetal bovine serum and 1%
Penicillan/Streptomycin/Fungicide (P/S?F)/S/F. SUM159
cells were cultured in Ham’s F12 with 5% calf serum, insulin
(5 μg/mL) and hydrocortisone (5 μg/mL). CAF-L cells were
generated as previously described [26,27]. 3T3-L1 and CAF-
L cells were cultured in (D)MEM supplemented with 10%
calf serum. All cells were grown at 37°C and 5% CO2. All
cell lines were tested negative for mycoplasma (MilliPROBE,
Millipore, Billerica, MA, USA); however, the identity of each
cell line was not authenticated in our laboratory.
Animals and surgery
All animal procedures were conducted in accordance
with a protocol approved by the Tufts University Institu-
tional Animal Care and Use Committee (IACUC). Col-
onies of Balb/c and NOD/SCID mice were maintained
in-house. NOD/SCID mice were maintained under asep-
tic sterile conditions. All mice were given food and water
ad libitum. Surgeries were performed under sterile con-
ditions, and animals received antibiotics in the drinking
water for two weeks after all surgical procedures.
For developmental studies (Figure 1C; Figure 2A-C),
the fourth inguinal mammary glands were removed from
eight-week old female Balb/c mice (nulliparous). For all
other developmental stages, eight-week old female Balb/c
mice were mated with eight-week old male Balb/c mice
and males were removed after the mice tested positive for
vaginal plugs. Glands were isolated from pregnant mice 10
days after vaginal plugs were present. Following partur-
ition, pups were allowed to nurse for five days at which
time lactating glands were isolated or ten days at which
time pups were removed to induce synchronous mam-
mary gland involution. Involuting mammary glands were
isolated three days after pups were removed and regressed
mammary glands were isolated 21 days after pup removal.
For tumor studies (Figure 1D-F), mice were monitored
weekly until palpable tumors formed, and tumor growth
was measured and recorded using calipers at least once
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Figure 1 Developmental stage of the mammary gland adipose tissue influences breast cancer growth. (A) Schematic of stages of
postnatal mammary gland development. (B) Representative H & E-stained sections of mammary glands isolated at five stages of development.
Scale bar = 100 μm. (C) Diagram depicting experimental strategy and timepoints of in vivo mammary gland injections and adipose tissue isolation.
See Methods for specific details. (D) 4 T1-12B cells were injected into the fourth inguinal fat pad of Balb/c mice at each developmental timepoint
(n = 10 per group). Tumor weight was normalized to the nulliparous group. (E) The tumor growth curve of mice injected at eight weeks (nulliparous)
of age with 4 T1-12B cells co-mixed with mouse adipose stromal cells (n = 10 per group). P values indicate significance compared to nulliparous mice.
Data are means ± SEM. (F) Tumor growth curve of mice injected at eight weeks of age with COMMA-D cells co-mixed with mouse adipose stromal
cells (n = 10 per group). P value indicates significance compared to nulliparous. Data are means ± SEM. SEM, standard error of the mean.
Figure 2 (See legend on next page.)
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per week thereafter. For direct injections (Figure 1D),
female Balb/c mice were mated at eight-weeks of age
and injected into the fourth inguinal mammary gland.
Due to the large number of mice needed per group and
the coordination required to have all the mice develop-
mentally synchronized, not all groups were injected at
the same time. Rather, for each developmental stage, a
nulliparous cohort control group was injected in parallel
on the same day as a particular developmental stage with
identical 4 T1-12B cells. This strategy was employed to
control for the different injection dates for each cohort
and any possible differences in the biology of the same
4 T1-12B cells on a given day. 4 T1-12B cells were re-
suspended in 3:1 media/Matrigel solution and injected
at a total of 5,000 cells per gland on the first day of each
developmental stage. Since we intentionally utilized a
tumor model that forms tumors in approximately three
weeks, and pregnancy, lactation, and involution are all
naturally approximately 21 days (three weeks) in the
mouse [28], one is able to compare the effects of the de-
velopmental stages to tumorigenesis. Tumors were ex-
tracted and weighed at 21 days. For co-mix experiments
(Figure 1E-F) cells were resuspended in 3:1 media/Matrigel
solution (5,000 4 T1-12B : 750,000 adipocytes; 250,000
Comma D : 750,000 adipocytes or 250,000 SUM159 :
750,000 CAF-L) and injected orthotopically into eight-
week old nulliparous female Balb/c mice or eight-week
nulliparous female NOD/SCID mice. Mice were monitored
until palpable tumors formed, and tumor growth was mea-
sured and recorded using calipers two times a week there-
after. All tissues were embedded in either paraffin or
optimal cutting temperature (OCT) compound, sectioned
and stained for H & E at Tufts Medical Center.
Primary tissue isolation and culture
All human breast tissue procurement for these experiments
was obtained in compliance with the laws and institutional
guidelines, as approved by the Institutional Review Board
(IRB) committee from Tufts Medical Center and University
of Massachusetts Medical School. Primary breast tumor tis-
sues were obtained at Tufts Medical Center and University
of Massachusetts Medical School. Disease-free breast tis-
sues were obtained from discarded material of patients
undergoing elective reduction mammoplasty at Tufts Med-
ical Center and, therefore, informed consent is not required.
Breast tissues were minced and enzymatically digested over-
night with a mixture of collagenase and hyaluronidase as
previously described [28,29]. Large clusters of undigested
tissue were allowed to settle and the supernatant enriched
for the adipocyte and stromal vascular factions. Cells were
collected, washed and plated in serum containing medium
to enrich for mammary adipose stromal cells (ASCs or
carcinoma-associated fibroblasts (CAFs)). Cells were cul-
tured in (D)MEM supplemented with 10% calf serum and
1% P/S/F for less than five passages.
Adipose stromal cells were isolated from mouse adi-
pose tissue; it was divided into stromal and adipocyte
fractions as described previously [30]. Briefly, freshly ex-
cised tissue from the fourth inguinal subcutaneous fat
pads of Balb/c mice, was rinsed in PBS, minced and
digested for 45 minutes to 1 hour at 37°C in collagenase
and hyaluronidase. The fat pads were isolated from
eight-week old female mice (nulliparous), or female mice
that were mated and collected during pregnancy, lacta-
tion, involution, or following regression as described
above. The floating adipocyte fraction and the stromal-
vascular fraction were resuspended in (D)MEM and
plated with 10% fetal bovine serum and 1% P/S/F. All
in vivo and in vitro experiments with adipose tissue were
performed with low passage cells (<3 passages).
Differentiation assays
The adipocyte differentiation assay was conducted as fol-
lows: 100,000 low passage adipose stromal cells were plated
into six-well dishes and allowed to grow to confluence in
(D)MEM supplemented with 10% fetal bovine serum and
(See figure on previous page.)
Figure 2 Phenotypic modulation of adipocytes during mammary gland development. (A) Quantification of percent area per tissue
occupied by adipose stroma (AS) or parenchyma (P) using Spot software (n = 5 glands per stage). P values indicate significance compared to
nulliparous. (B) Representative H & E-stained sections of mammary gland adipocytes isolated from non-diseased mice. Arrows indicate lipolytic adipo-
cytes. (C) Average diameter (μm) of adipocytes. n = 3 glands per stage. P value indicates significance compared to nulliparous. (D) Quantitative RT-PCR
of FABP4 and HSL expression in adipose stromal cells. Data are presented as average 2(−ΔCt) ± SEM; n = 3 experiments. (E) Representative immunofluor-
escence images of adipose stromal cells isolated from lactating or regressed mammary gland and NIH3T3 cells (negative control), 3T3L1 cells (positive
control) with inset (no primary) for FABP4 (red) and counterstained for nuclei with DAPI (blue) (n = 3 per group). (F) Representative images of Oil Red
O staining and quantification (G) of adipose stromal cells. Line indicates untreated cells whose absorbance is set to one; n = 3 experiments. (H)
Quantification of glycerol secreted by adipose stromal cells normalized to lipoprotein lipase RNA levels. n = 3 experiments. (I) Quantitative RT-PCR of
Klf2, PPARγ, FABP4 in adipose stromal cells treated with adipocyte differentiation media. Data are presented as fold change in comparison to
undifferentiated cells. Horizontal black line indicates undifferentiated cells set to one. Bars above the black line indicate an increase in expression
compared to undifferentiated cells. Bars below the black line indicate a reduction in expression compared to undifferentiated cells. Data are presented
as average 2(−ΔΔCt) ± SEM. n = 3 experiments. (J) Gene set enrichment analysis of transcriptional signature of adipose stromal cells from lactating mice.
Scale bar = 100 μm. All data are means ± SEM. DAPI, 4′,6-diamidino-2-phenylindole; SEM, standard error of the mean.
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P/S/F. Two days post confluence the cells were treated
with differentiation media ((D)MEM supplemented with
10% fetal bovine serum, P/S/F, 0.5 mM IBMX (Sigma,
St. Louis, MO, USA), 0.1 μM dexamethasone (Sigma) and
0.5 μg/mL insulin (Sigma) three times a week for 21 days.
Cells were stained with Oil Red O, which was extracted
and quantified as previously described [31]. Images were
visualized using a Nikon Eclipse 80i inverted microscope
and captured with Spot Imaging software (Diagnostic
Instruments, Sterling Heights, MI, USA).
Immunohistochemistry and immunofluorescence
LYVE-1 (1:100; Abcam, Cambridge, MA, USA) immunohis-
tochemistry was performed on formalin-fixed, paraffin-
embedded tissue sections with sodium citrate antigen
retrieval, followed by detection with biotinylated secon-
dary antibody (1:200 anti-rabbit; Vector Laboratories) and
visualization with the Elite ABC Peroxidase Kit and DAB
substrate (Vector Laboratories, Burlingame, CA, USA). Nu-
clei were counterstained for hematoxylin. Immunofluores-
cence on frozen tissue or cultured cells was performed on
samples that were permeabilized with 0.1% Triton X-100
(Sigma) in PBS, washed and blocked in 1% BSA in
PBS at ambient temperature. Samples were incubated
with cellular retinoic acid binding protein-1 (crabp1) (1:250,
Abcam), CD31 (1:100, Invitrogen, Carlsbad, CA, USA), pan-
cytokeratin (1:100, DAKO, Carpinteria, CA, USA)) or
FABP4 (1:200, Cell Signaling Technology, Danvers, MA,
USA) overnight at 4°C. The fluorescence signal was detected
using secondary antibodies (1:500 conjugated Alexa488 and
Alexa588, Invitrogen). Nuclei were stained with 4′,6-
diamidino-2-phynylindole (DAPI) and images were captured
with the Spot imaging software system (Diagnostic Instru-
ments, Inc.). Quantification was performed using ImageJ
software. Immunofluorescence on frozen tissue sections was
performed as previously described for crabp1 [32].
Endothelial cell assays and culture
Primary mouse heart endothelial cells were obtained from
the Center for Vascular Biology Research at Beth Israel
Deaconess Medical Center. Briefly, hearts were isolated from
17-day-old Balb/c pups, minced and enzymatically digested
with collagenase. Endothelial cells were extracted in a two-
step immunomagnetic bead separation, first with CD31-
coated beads (Pharmingen, San Diego, CA, USA) then with
ICAM-coated beads (Pharmingen). Purified endothelial cells
were cultured in (D)MEM, 20% fetal bovine serum, P/S/F,
L-gln, NEAA, heparin, and endothelial cell growth supple-
ment (Biomedical Technologies, Stoughton, MA, USA).
The human, umbilical cord endothelia cell (HUVEC)
line was obtained from Dr. Guo-fu Hu (Tufts Medical
Center) and cultured in endothelial cell media (Invitrogen)
with 5% fetal bovine serum and basic fibroblast growth
factor (bFGF) (20 ng/mL).
Conditioned media were collected from low passage
adipose stromal cells isolated from three separate mice
or three independent patients. Assays using mouse or
human conditioned media were conducted identically.
In the proliferation assay, 50,000 endothelial cells were
plated in a 24-well plate in growth media. Six hours after
plating, cells were washed and treated with conditioned
media from adipocytes. Cells were counted 36 hours
after exposure to conditioned media.
In the wound healing assay, 300,000 endothelial cells
were plated in a 12-well plate. Six hours after plating
cells were washed and refed with (D)MEM supple-
mented with 2% fetal bovine serum. Twenty-four hours
after plating, cells were washed with PBS, scratched with a
pipet tip, treated with conditioned media and imaged
(0 hour timepoint). Cells were imaged again six hours
later. Wound closure was calculated using Spot software.
In the tube forming assay, 30,000 endothelial cells
were plated onto a 96-well plate coated with Matrigel
and treated with conditioned media from stromal cells.
Five hours after plating, images were captured.
Microarray
Total RNA was extracted from low passage adipose stromal
cultures isolated from nulliparous, lactating and involuting
mammary glands of female Balb/c mice (Figure 1B) with the
RNAeasy Mini Kit (Qiagen, Valencia, CA, USA). Synthesis
of cDNA from total RNA and hybridization/scanning of mi-
croarrays were performed with Affymetrix (Santa Clara, CA,
USA) GeneChip products (Affy Mouse Gene 1.0 ST) as de-
scribed in the GeneChip manual. Raw data files (.CEL) were
converted into probe set values by Robust multi-array average
normalization. Robust multi-array average expression values
were computed from arrays using R and Bioconductor soft-
ware. After normalization, genes not detected on all of the ar-
rays and those with little variation (<0.05) in the signal across
the arrays were removed from further consideration. To com-
pare gene expression between different tissue phenotypes,
linear models were derived using LIMMA, also part of the
Bioconductor package. The significance levels of the compari-
sons were estimated by empirical Bayes methods. All micro-
array data can be accessed in the Gene Expression Omnibus
(GEO) database using the accession number GSE53044.
For pathway analysis, gene set enrichment analysis was
performed using the GenePattern gene set enrichment ana-
lysis (GSEA) module. Gene sets for the mus musculus gen-
ome were obtained from the Walter and Eliza Hall Institute
(WEHI, Parkville VIC, Australia). Enriched gene sets with a
false discovery rate (FDR) of less than 25% were identified
as interesting. The normalized log 2 ratios of probes map-
ping to the same gene (defined by gene symbols) were aver-
aged to generate independent expression estimates, and the
resulting matrix data were median-centered.
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RT-PCR analysis
Total RNA was isolated and purified using a RNAeasy
kit (Qiagen). RNA was reverse transcribed to cDNA
using an iScript cDNA synthesis kit (Biorad, Hercules,
CA, USA). Quantitative real-time PCR analysis was per-
formed using SyBR Green and an iCycler thermocycler
(Bio-Rad) and analyzed via the delta delta Ct method
[33-35]. Primer sequences used for quantitative real-
time PCR are listed in Additional file 1.
Lipolysis assay
A total of 1,000 low passage ASCs were plated in a 96-
well plate, allowed to grow to confluence for one week
and then treated with differentiation media for three
weeks. Glycerol levels were measured using the 3 T3-L1
lipolysis assay kit according to the manufacturer’s proto-
col (Zen-Bio, Research Triangle Park, NC, USA).
Tumor necrosis quantification
Hematoxylin and eosin staining was performed on
formalin-fixed, paraffin embedded tumor sections and
necrosis was quantified across the entire tumor tissue
using ImageJ software. Percent necrosis was calculated
as the area of necrosis divided by the total area of the
tumor.
Statistical analysis
For the microarray, significance levels of the compari-
sons were estimated by empirical Bayes methods. All
other analyses were done using a two-tailed Student’s t
test.
Results
Local and systemic factors during lactation promote
breast cancer
To study PABCs in vivo, we utilized a model we previ-
ously described [36] in which carcinoma cells are intro-
duced directly into the fourth inguinal mammary glands
of mice at the five major stages of postnatal develop-
ment: post-pubertal (nulliparous), pregnancy, lactation,
involution and upon full regression of the gland follow-
ing involution (Figure 1A-C). To limit overlap of tumor
growth across different developmental stages, we utilized
a syngeneic model of triple negative basal like breast
cancer that rapidly forms primary mammary carcinomas
within three weeks (Figure 1C).
Consistent with earlier findings [16,19], 4 T1-12B car-
cinoma cells formed larger tumors in involuting mam-
mary glands relative to nulliparous glands (P = 0.03)
(Figure 1D). However, tumors harvested from pregnant
and lactating mice were on average 3.5-fold larger than
their counterparts in nulliparous mice (201 mg versus
58 mg; P <0.01) and 2-fold larger than in involuting
mice (201 mg versus 98 mg; P = 0.045) (Figure 1D,
Additional file 2). These results suggest that factors
present during pregnancy and lactation contribute more
strongly to tumor growth than during involution. Due to
the aggressive nature of the 4 T1-12B model, no obvious
histopathological differences were observed between
4 T1-12B tumors that formed between the different
stages of mammary gland development.
Circulating levels of estrogen and progesterone are at
their highest during pregnancy, while the levels of pro-
lactin, a potent mitogen for breast cancer cells, are at
their peak during pregnancy and lactation [37,38]. Since
these hormones are powerful modulators of mammary
epithelial cell proliferation, the accelerated breast tumor
growth during pregnancy and lactation could be due to
differences in systemic hormone levels. An alternative
possibility is that local alterations in cellular composition
and phenotypes within the mammary gland microenvir-
onment could be sufficient to promote the observed in-
crease in tumor growth during pregnancy and lactation.
To evaluate the latter possibility, we co-mixed 4 T1-12B
cells with the ASCs isolated from mice at each develop-
mental stage and injected the co-mixture into nullipar-
ous mice. Since nulliparous mice have comparable
systemic hormone profiles, any differences in tumor
growth would be attributable to the admixed stromal
cells.
Although injection into mammary glands of pregnant,
lactating and involuting mice accelerated tumor forma-
tion in the experiments above (Figure 1D), only ASCs
derived from lactating mammary glands could accelerate
4 T1-12B mammary tumor growth in nulliparous mice
(P <0.001, Figure 1E). To determine whether the differ-
ence in tumor growth rates might be associated with dif-
ferential cell survival following implantation, injection
sites of early 4 T1-12B tumors were evaluated and viable
cells were observed within the mammary glands one
week following injection, suggesting that the delay in
early tumor growth was not due to immune clearance of
cells or increased cell death. To test whether the tumor-
enhancing effects of ASCs derived from lactating mam-
mary glands extended to other breast epithelial models,
we repeated the above experiment with COMMA-D
cells, which are weakly to non-tumorigenic and when
transformed also model triple negative basal like breast
cancers [39]. While COMMA-D cells did not form large
tumors when injected alone, they did grow slowly when
co-mixed with ASCs from nulliparous, pregnant, invo-
luting or regressed mammary glands. There was a trend
towards faster growth in the tumors co-mixed with
ASCs isolated from pregnant and involuting glands;
however, this trend was not statistically significant. In
contrast to ASCs from other stages of development, co-
mixture with ASCs from lactating glands resulted in sig-
nificant acceleration of tumor formation by COMMA-D
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cells (P = 0.03, Figure 1F). These findings indicate that
while systemic factors likely play a key role in the devel-
opment of tumors during pregnancy and involution,
local alterations in either adipose stromal cell compos-
ition or function during lactation strongly contribute to
breast cancer growth.
Characterization of the adipose stroma during mammary
gland development
The proportion of the mammary gland occupied by
stroma is known to vary significantly depending on the
differentiation state of the adjacent epithelium [22]. We,
therefore, undertook a detailed histological and cellular
analysis of the adipose stroma across the different
stages of post-natal development to characterize stro-
mal adipocyte remodeling during different mammary
epithelial differentiation stages. Quantification of adipo-
cyte occupancy revealed that they occupy the largest
proportion of the gland in nulliparous and regressed
glands (97.2% and 96.1%, respectively), while adipocytes
comprise the smallest proportion of the gland during
lactation (11.4%, P <0.001, Figure 2A). Adipocytes
present in nulliparous and regressed tissues were vari-
ably sized and were both multilocular and unilocular
(Figure 2B). In contrast, adipocytes present in pregnant
mice were uniquely unilocular and significantly larger in
size, consistent with a lipid storage phenotype (P <0.001,
Figure 2C). Notably, adipocytes present in lactating tissues
were markedly distinguishable from adipocytes in any
other developmental stage. Not only were lactation-associ-
ated adipocytes significantly smaller in size (P = 0.01) but,
more importantly, they exhibited features consistent with
lipolysis [40] including prominent membrane folding and
vesicle formation (Figure 2B arrows).
To examine further the mammary stroma, ASCs were
isolated from mammary fat pads of several mice at dif-
ferent developmental stages. Although ASCs consist of
heterogeneous populations of cell types including adipo-
cyte stem cells, preadipocytes, mature adipocytes and
other stromal cells, we found that the ASCs from all de-
velopmental stages isolated from three different mice all
expressed similar levels of mature adipocyte markers
including FABP4 and HSL (Figure 2D,E) indicating
that the representation of mature adipocytes within
the cultures was similar. However, when examined for
their ability to accumulate and store lipid, Oil Red O
staining revealed that ASCs from lactating glands failed
to accumulate lipid while ASCs from nulliparous, preg-
nant, involuting and regressed glands all induced sig-
nificant lipid accumulation under identical conditions
(Figure 2F,G).
Since the lactating-derived ASCs failed to accumulate
lipid, we reasoned this might be due to (1) the ability to
retain lipid (lipid metabolism) differed between ASCs
isolated from different developmental stages, (2) the in-
duction of adipogenic differentiation differed between
ASCs isolated from different developmental stages, or
(3) there were significant differences in the representa-
tion of cell types within ASCs isolated from different de-
velopmental stages that could affect lipid accumulation.
To evaluate these possibilities, we assayed ASCs from
mammary glands of nulliparous, pregnant, lactating and
regressed mice for lipolyis, adipogenesis and cellular
composition.
Lipid metabolism is maintained by the highly regulated
balance of lipogenesis and lipolysis [41]. During lipid ca-
tabolism, lipids are broken down into glycerol and free
fatty acids, a process that can be measured biochem-
ically. We quantified the levels of glycerol released from
ASCs under differentiation conditions and compared
them to the expression level of lipoprotein lipase, an en-
zyme required for lipogenesis [42]. ASCs isolated from lac-
tating mammary glands exhibited a significantly higher
ratio of lipolysis to lipogenesis compared to nulliparous-
and pregnant-derived cells (P = 0.01, Figure 2H, Additional
file 3).
Adipocyte differentiation involves a stepwise program
triggered by the suppression of Klf2 expression with the
concomitant induction of PPARγ and FABP4 [43]. We
observed that ASCs isolated from all developmental
stages, including lactation, were able to activate PPARγ
and FABP4 expression and repress Klf2 expression in re-
sponse to differentiation conditions (Figure 2I). However,
compared to ASCs from other stages, the magnitude of
PPARγ and FABP4 induction in ASCs from lactating and
involuting mammary glands was reduced, suggestive of an
attenuated, although not blocked, differentiation potential
of adipocytes.
We examined ASC cultures for the presence of other
contaminating mesenchymal cell types that could affect
adipogenesis including preadipocytes (Pref1), endothelial
cells (CD31), angioblasts (CD34), mesenchymal stem
cells (Sca-1 and CD29) and macrophages (F4/80). How-
ever, no significant differences were observed between
ASCs derived from lactating mammary glands compared
to any of the other developmental stages that could ac-
count for their failure to undergo adipogenesis or lipid
accumulation (Additional file 4). Furthermore, gene-
expression profiling of ASCs from nulliparous, involut-
ing and lactating mammary glands from multiple mice
indicated that very few genes were differentially expressed
(Additional files 5, 6 and 7). GSEA further revealed that
ASCs from lactating mammary glands were highly
enriched in genes associated with adipocytes including
linoleic acid metabolism (P <0.0001), phospholipase A2
activity (an enzyme that releases fatty acids from glycerol,
P <0.0001) and lipid homeostasis (Figure 2J, P = 0.012).
Together, these results suggest that ASCs from lactating
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mammary glands (hereafter termed lactation-derived adi-
pose cells (ASC-Ls)) are enriched in adipocytes that are
lipolytic, unable to accumulate lipid and are unable to fully
execute the adipogenic differentiation program.
Tumor-promoting functions of ASC-Ls
To determine the functional properties of ASC-Ls their
gene expression signature was queried for known bio-
logical process by GSEA. ASC-Ls were enriched in genes
involved in extracellular matrix production, immune/in-
flammatory response and cytokine-cytokine receptor in-
teractions compared to nulliparous-derived adipose cells
(ASC-Ns) or involuting derived adipose (ASC-Is) cells
(Figure 3A, 3B; Additional files 8, 9, 10 and 11). In
addition, compared to ASC-Ns or regressed-derived adi-
pose cells (ASC-Rs), ASC-Ls were highly enriched in the
gene set termed ‘tumor angiogenesis’ (P <0.0001) and, to
a lesser degree, ‘angiogenesis’ (Figure 3A, 3B; Additional
files 8, 9 and 10). This finding prompted us to assess
whether the tumor promoting activity of ASC-Ls might
be through angiogenesis.
Primary mouse heart endothelial cells (MHECs) were
treated with conditioned medium (CM) harvested from
ASC-Ns, ASC-Rs or ASC-Ls and examined for prolifera-
tion, wound healing and tube formation. Increased pro-
liferation of MHECs was observed following stimulation
with CM from ASC-Ls (P <0.001) compared to cells
treated with CM from ASC-Rs (Figure 3C). MHEC tube
formation was also significantly augmented in the pres-
ence of CM from ASC-Ls compared to CM from ASC-
Ns or ASC-Rs (P <0.001, Figure 3D, Additional file
12A). Furthermore, wound healing assays revealed that
MHECs migrated significantly faster when treated with
CM from ASC-Ls when compared to CM from ASC-Ns
or ASC-Rs (P = 0.01, Figure 3E).
To determine if the increased angiogenic and inflam-
matory activity of ASC-Ls was contributing to their abil-
ity to accelerate tumor formation, 4 T1-12B cells were
co-mixed with ASC-Rs or ASC-Ls and injected into nul-
liparous mice. Macrophage recruitment and tumor
angiogenesis was assessed by immunofluorescence (IF).
No significant difference was found in the number of
F4/80 positive macrophages recruited to tumors derived
from 4 T1-12B cells alone, 4 T1-12B cells co-mixed with
ASC-Ls or 4 T1-12B cells co-mixed with ASC-Rs (Add-
itional file 12B). However, there was a 10-fold increase
in the number of CD31 positive endothelial cells present
within tumors derived from 4 T1-12B cells co-mixed
with ASC-Ls (P <0.001, Figure 3F) compared to tumors
from 4 T1-12B cells alone or from 4 T1-12B cells co-
mixed with ASC-Rs.
Given these findings, the expression of secreted pro-
angiogenic growth factors implicated in angiogenesis (vas-
cular endothelial growth factor-A, -C, -D (VEGF-A,
VEGF-C, VEGF-D), matrix metalloproteinase-9 (MMP-9),
IL-6, placental-like growth factor (PlGF) and platelet-
derived growth factor (PDGF-C)) was examined in ASC-
Ls (Figure 3G and Additional file 12C). Only the levels of
VEGF-D and IL-6 were significantly elevated in ASC-Ls
compared to ASC-Ns or ASC-Rs. Consistent with the
function of these factors, tumors derived from 4 T1-12B
cells co-mixed with ASC-Ls showed an increase in Lyve-1
staining (a marker of lymphatic endothelial cells) com-
pared to tumors derived from 4 T1-12B cells co-mixed
with ASC-Rs (Figure 3H). Collectively, these results indi-
cate that ASC-Ls accelerate tumor growth through their
increased angiogenesis.
Phenotypic modulation of ASC-Ls is regulated by crabp1
To determine how ASC-Ls are regulated, we conducted
analyses of the ranked genes that were differentially
expressed between ASC-Ls, ASC-Ns and ASC-Rs. In
doing so, we found that crabp1 was one of the most sig-
nificantly differentially expressed genes in ASC-Ls com-
pared to ASC-Ns or ASC-Rs (Figure 4A). Crabp1 has
been well studied for its role as a binding protein for retin-
oic acid [44,45], but its role in regulating lipid metabolism
or adipocyte differentiation is less well understood [46].
In agreement with the microarray analysis, we con-
firmed that crabp1 mRNA and protein levels were
highly expressed in ASC-Ls (Figure 4B,C). Crabp1
mRNA was overexpressed approximately five-fold in
ASC-Ls (L) compared to any other developmental stage
(N, P, R: P = 0.003; I: P = 0.04). Likewise, crabp1 protein
was most abundantly expressed in ASC-Ls. Crabp1 ex-
pression was also examined within mammary tissues
from different developmental stages by IF (Figure 4D).
Abundant levels of crabp1 protein expression were
found localized within adipocytes in mammary glands
during lactation (arrows) but not in adipocytes from
mammary glands of nulliparous or regressed mice.
To determine whether crabp1 expression is directly
regulating the adipogenic phenotype of ASC-Ls, lentiviral-
mediated short hairpin-inhibition was used to target
crabp1 expression. Crabp1 gene expression was reduced
by 86% when compared to cells treated with scrambled
shRNAs (P = 0.01; Figure 4E). Crabp1 inhibition led to a
dramatic increase in lipid accumulation under differenti-
ation conditions (Figure 4F,G). Furthermore, inhibition of
crabp1 expression resulted in a marked decrease in the
levels of glycerol release relative to lipoprotein lipase ex-
pression from cultures of adipocytes upon differentiation
compared to control ASC-Ls (Figure 4H, P = 0.03).
To determine whether phenotypic modulation though
crabp1 was responsible for the tumor promoting ability
of ASC-Ls, 4 T1-12B tumor cells were co-mixed with
ASC-Ls in which crabp1 was inhibited and injected into
nulliparous mice. Tumor cells co-mixed with shCrabp1-
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ASC-Ls grew significantly slower (P = 0.02, Figure 4I)
and were significantly smaller (P <0.001, Figure 4J)
than tumors derived from 4 T1-12B cells co-mixed with
either control ASC-Ls or shScram-ASC-Ls. In addition a
three-fold decrease in VEGF-D expression was observed
upon inhibition of crabp1 expression when compared to
shScram-ASC-Ls cells (P = 0.01, Figure 4K). Endothelial
tube formation was also inhibited in endothelial cells
treated with media isolated from shCrabp1-ASC-L cells
(Figure 4L). Taken together, these findings indicate that
the tumor promoting phenotype of ASC-Ls, which can
be modulated by crabp1, is important for angiogenesis.
Breast carcinoma-associated fibroblasts phenocopy ASC-Ls
In examining the functional properties of ASC-Ls, GSEA
revealed that ASC-Ls were unexpectedly enriched in
genes expressed in CAFs (Figure 5A, P = 0.03). Addition-
ally, an enrichment of genes associated with tumorigen-
esis (P = 0.01) and breast cancer progression (P = 0.04)
was also found in ASC-Ls (Figure 5A and Additional
files 13, 14 and 15). These findings suggest that CAFs
may share similarities with ASC-Ls and likewise be regu-
lated by the same mechanisms that regulate ASC-Ls.
Indeed, consistent with their known angiogenic functions
[47], CAF-CM significantly stimulated both the prolifera-
tion (P < 0.001, Figure 5G) and migration (P = 0.002,
Figure 5H) of HUVECs compared to control cells iso-
lated from disease-free reduction mammoplasty tissues.
When examined for features of ASC-Ls including ele-
vated crabp1expression, expression of adipocyte markers,
features of lipolysis and a failure to undergo adipogenic
differentiation, CAFs exhibited remarkable similarities to
ASC-Ls. Compared to the normal adipose stroma of
disease-free human breast tissue (Figure 5B left), the adi-
pocytes adjacent to human xenografted tumors (Figure 5B
middle) or adjacent to breast carcinomas in patient tu-
mors (Figure 5B right) frequently exhibited features of
lipolytic adipocytes including membrane blebbing and de-
creased adipocyte diameter. Isolated CAFs from breast
tumor specimens (n = 6) were examined for the ex-
pression of adipocyte markers and lipid accumulation
and compared to adipose cells isolated in the identical
manner from reduction mammoplasty adipose (RMA,
n = 8). Notably, CAFs expressed leptin and FABP4, two
markers of mature adipocytes (Figure 5C, D), yet failed
to accumulate lipid and undergo adipogenesis compared
to RMAs (P = 0.03, Figure 5E).
Immunofluoresence of orthotopic xenograft breast tu-
mors revealed that crabp1 expression was absent in
tumor cells (green) but highly expressed within the des-
moplastic fibroblastic tumor-associated stroma (red) in
all samples tested (Figure 5F, Additional file 16). Crabp1
was also expressed within the tumor-associated stroma
of patient-derived primary human breast cancer tissues
(Figure 5F, Additional files 16, 17 and 18).
Phenotypic modulation of CAFs is regulated by crabp1
Since these above findings indicate that CAFs exhibit
many of the molecular and functional features of ASC-
Ls, we wanted to determine whether the expression of
crabp1 could also regulate the tumor promoting phenotype
of CAFs. To this end, we generated CAF-like (CAF-L) cells
as previously described [26], since we were unable to
genetically manipulate primary CAFs due to their lim-
ited lifespan in culture. Consistent with prior findings
[26], CAF-L cells exhibited many of the features of pri-
mary CAFs including the ability to accelerate tumor
growth (P = 0.04, Figure 6A).
Inhibition of human crabp1 in CAF-L cells using
lentiviral-mediated short hairpin led to a reduction of
crabp1 gene expression by 96% compared to cells in-
fected with control shRNA (shScr) (Figure 6B). Notably,
inhibition of crabp1 in CAF-L cells led to increased
intracellular lipid accumulation (P = 0.03, Figure 6C). To
determine if phenotypic modulation of fibroblasts was
restricted to CAF-L cells, we also inhibited crabp1 ex-
pression in NIH3T3 fibroblasts, which express abundant
levels of crabp1 (Additional file 19). Similar to the
(See figure on previous page.)
Figure 3 ASC-Ls promote tumors through increased vasculogenesis. (A) Gene ontology biological process categories associated with
adipose stromal cells from lactating mice compared to mammary adipose stromal cells from nulliparous or involuting mice. The DAVID
Functional Annotation Tool was used to define categories with an enrichment score >1.5, and the number of genes represented in the list and
the P value of genes differentially expressed in the microarray are shown. (B) Gene set enrichment analysis indicates that ASC-Ls exhibit increased
expression of genes associated with cytokine production and tumor angiogenesis. (C-E) Endothelial cell assays using primary mouse heart
endothelial cells treated with conditioned media collected from ASCs isolated from nulliparous, lactating or regressed glands (ASC-N, ASC-L or
ASC-R, respectively), n = 3 per group. Data are presented as means ± SEM (C) Proliferation assay day 3. Data are presented as means ± SEM. n = 3
experiments. (D) Quantification of tube formation assay four hours after plating. Data are presented as means ± SEM. n = 3 experiments. (E)
Representative image and quantification of wound healing assay six hours after addition of conditioned media. Data are presented as means ±
SEM. n = 3 experiments. (F) Representative immunofluorescence and quantification of 4 T1-12B tumors co-mixed with adipocytes for CD31 (red)
and counterstained for nuclei with DAPI (blue) (n = 4 per group). Data presented as means ± SEM. (G) Quantitative RT-PCR of VEGF-A, VEGF-D,
MMP-9 and IL-6 in ASC-N, ASC-R or ASC-L. Data are presented as average 2(−ΔCt) ± SEM; n = 3 experiments. (H) Representative images of
immunohistochemistry of 4 T1-12B tumors co-mixed with adipocytes for LYVE-1. n = 3 experiments. Scale bar = 100 μm. ASC-L, lactation-derived
adipose stromal cells; ASC-N, nulliparous-derived adipose stromal cells; ASC-R, regressed-derived adipose stromal cells; DAPI, 4′,6-diamidino-2-phenylindole;
MMP-9, matrix metalloproteinase 9; SEM, standard error of the mean; VEGF, vascular endothelial growth factor.
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Figure 4 Phenotypic modulation of adipocytes is regulated by Crabp1. (A) Overlap of differentially regulated genes in adipocytes. (B) qRT-
PCR of crabp1 transcript in adipocytes isolated from the fourth inguinal mammary gland. (N = nulliparous, P = pregnant, L = lactation, I = involu-
tion, R = regressed). Data are presented as average 2(−ΔCt) ± SEM; n = 3 experiments. (C) Western blot of crabp1 protein in adipocytes as in (B). (D)
Immunofluorescence of crabp1 (red) and cytokeratin (green) in mammary glands; DAPI nuclear counterstain (blue). Arrows indicate adipocytes that are
crabp1 positive. Scale bar = 100 μm. (E) qRT-PCR of crabp1 transcript in ASC-L treated with shRNA for crabp1 or scrambled control. Data are presented
as average 2(−ΔΔCt) ± SEM; n = 3 experiments. (F) Representative images of Oil Red O staining of ASC-L transduced with shRNA (crabp1 or scrambled
control) and exposed to adipocyte differentiation media. (G) Quantification of Oil Red O staining from (F). Data are presented as average absorbance ±
SEM. Untreated cell absorbance is set to one; n = 3 experiments. (H) Quantification of glycerol secreted by ASCs normalized to lipoprotein lipase
RNA levels. n = 3 experiments. (I) Tumor growth curve and tumor weight (J) of mice injected at eight weeks with 4 T1-12 B cells co-mixed with
untreated ASC-L or ASC-L transduced with shRNA (crapb1 or scrambled control) (n = 10 per group). P value indicates significance compared to
shScram-ASC-L. Data are means ± SEM. (K) qRT-PCR of VEGF-D in ASC-Ls transduced with shRNA for crabp1 or scrambled control. Data are presented
as average 2(−ΔΔCt) ± SEM; n = 3 experiments. (L) Quantification of tube formation of primary mouse heart endothelial cells treated with media collected
from ASC-Ls transduced with shRNA (crabp1 or scrambled control). Data are presented as means ± SEM. n = 3 experiments. ASC-L, lactation-derived
adipose stromal cells; crabp1, cellular retinoic acid binding protein-1; DAPI, 4′,6-diamidino-2-phenylindole; SEM, standard error of the mean.
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findings in CAF-L cells, knockdown of crabp1 in
NIH3T3 cells led to a dramatic induction of adipogene-
sis and accumulation of lipid under differentiation con-
ditions (P = 0.03, Figure 6D).
To determine whether the phenotypic switch of CAFs
affects their ability to promote tumor growth, the Basal
B SUM159 breast cancer cell line was co-mixed with
either shScr-CAF-L or shCrabp1-CAF-L cells and
injected into NOD-SCID mice. Indeed, phenotypic
modulation of CAF-L cells abolished their tumor pro-
moting activity (Figure 6E, P = 0.01). This failure to
accelerate SUM159 xenografts was attendant with a sig-
nificant reduction in the density of the tumor-associated
vasculature (Figure 6F) and resulted in extensive and sig-
nificant regions of centralized tumor necrosis, which
was essentially absent in tumors from SUM159 cells co-
mixed with shScr-CAF-L cells (Figure 6G, P = 0.03).
Since tumor necrosis is a well-established feature of lim-
ited angiogenesis, these findings, combined with those
above, support the notion that crabp1 expression affects
the tumor promoting activities of CAFs by modulating,
in part, tumor angiogenesis.
Discussion
It is well known that pregnancy and lactation confer
long term protective effects in lowering the lifetime risk
of developing breast cancer [48-50]. However, approxi-
mately 3% of women are diagnosed with breast cancer
during pregnancy and lactation [13], and PABCs are
more aggressive in nature compared to age-adjusted
breast cancers within this age group [10,13,15,20,21].
Thus, a better understanding of the etiology and patho-
genesis of PABCs is imperative for improved diagnosis
and therapeutic strategies for pregnant and lactating
women.
The systemic and microenvironmental changes during
post-lactational involution have been best recognized for
their role in the pathogenesis of PABCs [16,17,19,51,52].
In particular, studies have elucidated that the main
drivers of tumor promotion in post-lactational involu-
tion are due to changes to the extracellular matrix as
well as an infiltration of inflammatory macrophages. Our
data demonstrate that the microenvironment of lactation
may also play a role in progression of PABC. Significant
epidemiological data indicate that PABCs diagnosed dur-
ing lactation have an overall poorer prognosis than those
diagnosed during involution [10,13,15,20,21]. However,
these studies do not dissect the role of lactation specific-
ally, by comparing breastfeeding and non-breastfeeding
women. Further epidemiologic studies in these popula-
tions would clarify the relationship between lactation
and involution in tumor promotion.
Consistent with the clinical observations, we found
that breast cancer growth was significantly augmented
when carcinoma cells were introduced into mammary
glands of pregnant or lactating mice compared to cells
injected into involuting mice. Our study is the first to
assess the role of all stages of pregnancy on PABCs
(Figure 1D-F). Data presented herein indicate that the
lactating microenvironment is a strong driver of tumor
progression suggesting that if a pre-existing tumor were
present in the breast at the time of lactation, the lactat-
ing microenvironment could promote that tumor to be
more aggressive than if the tumor were present during
other stages of pregnancy. Our data show that ASCs
present during lactation were the major affecters of
breast tumorigenesis during this stage. It is important
to note that lactating ASCs have never been implicated
as a potential cause/promoter of increased aggressive-
ness. It also should be noted that these cells were iso-
lated from non-diseased tissues yet they still have the
ability to promote tumors when compared to any other
stage of mammary gland development. These findings
imply that both systemic and local factors are import-
ant for the pathobiology of PABCs and that the stromal
changes during lactation under normal physiological
conditions play a distinct and important role in the
progression of PABCs that are different from those dur-
ing post-lactational involution.
We found that lactating ASCs express increased levels
of inflammatory cytokines, are highly angiogenic and are
growth promoting. Furthermore, we found that expression
(See figure on previous page.)
Figure 5 CAFs phenocopy ASC-Ls. (A) Gene sets enriched in ASC-Ls. (B) Representative H & E-stained sections of normal human mammary
gland adipocytes (left), human mammary carcinoma (middle) and human xenograft breast cancer (right). Arrows and inset indicate prominent
membrane folding. Scale bar = 100 μm. (C) Quantitative RT-PCR of leptin and FABP4 in RMA and CAFs from various patient samples. Data are
presented as average 2(−ΔΔCt) ± SEM. (D) Representative image of immunofluorescence of RMAs and CAFs for FABP4 (red) and counterstained for
nuclei with DAPI (blue) (n = 3 per group). (E) Representative images of Oil Red O staining and quantification of adipose tissue from reduction
mammoplasty (RMA) (n = 8) and carcinoma associated fibroblasts (CAF) (n = 6) treated with adipocyte differentiation media. Data are presented as
average absorbance ± SEM. Untreated cell absorbance is set to one. (F) Immunofluorescence of human mammary carcinoma either as xenografts
in the HIM model (n = 4) or primary human breast cancer tissues, n = 10. Crapb1 (red) cytokeratin (green) showing both positive (#1 to 3) and
negative expression (neg). (G-H) Endothelial cell assays using HUVECs treated with conditioned media collected from RMAs or CAFs, n = 3 per
group. Data are presented as means ± SEM. (G) Proliferation assay day 3. (H) Quantification of wound healing assay six hours after addition of
conditioned media. Scale bar = 100 μm. ASC-L, lactation-derived adipose stromal cells; crabp1, cellular retinoic acid binding protein-1; DAPI,
4′,6-diamidino-2-phenylindole; HUVEC, human umbilical cord endothelial cells; SEM, standard error of the mean.
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of crabp1 in lactating ASCs was responsible for their fail-
ure to retain lipid and undergo adipogenesis. It is interest-
ing that the abundance of such cells and their expression
of crabp1 appear to be restricted to lactation and cancer.
This suggests that the appearance of these ASCs may be
important during conditions of high nutritional demand
where they perform important functions to meet those de-
mands (Figure 6H). Indeed, during pregnancy and lacta-
tion, the mammary gland undergoes a notable expansion
in parenchyma when additional energy is required for cel-
lular proliferation and expansion of the tissue (Figure 2).
Likewise, during breast cancer growth, expanding carcin-
oma cells require further energy and angiogenic needs. By
regulating lipogenesis and lipolysis, adipocytes can main-
tain the appropriate energy balance necessary to meet the
nutritional demands of an expanding normal or malignant
epithelial cell population [53]. Our findings suggest that
CAFs may have reactivated the same pro-angiogenic, in-
flammatory, growth-promoting program that is present
during lactation. Under developmental and pathological
conditions, this program exists to satisfy the demands
placed on the growing tissue. However, during breast can-
cer, activation of this adipose stromal developmental pro-
gram is co-opted to further fuel tumor growth.
Our data indicate that by regulating adipogenesis and
lipid metabolism, ASCs can acquire angiogenic and
tumor growth promoting characteristics. Reduction in
the levels of crabp1 in CAF-like cells not only shifted
lipid metabolism towards lipid accumulation, but it also
abolished tumor promoting activity. Our findings and
recent observations by others indicate that CAFs exhibit
many features of ASCs including adipogenesis, lipid ac-
cumulation and expression of mature adipocyte markers,
albeit at attenuated levels compared to ASCs from
disease-free breast tissues [54]. Furthermore, we, along
with others, have found that adipocytes adjacent to
breast cancers exhibit features of lipolysis [55]. Indeed,
adipocytes co-cultured with breast cancer cells have
been shown to release their lipid [55] suggesting signals
derived from cancer cells promote lipolysis. Such adipo-
cytes, termed cancer-associated adipocytes (CAAs) also
over-express matrix proteins and inflammatory cytokines
[55]. These similarities, combined with our findings, sug-
gest that adipocytes may be an important and major
source of CAFs in breast tumors tissues through activa-
tion of crabp1 expression (Figure 6G).
We have found that crabp1 levels are induced and
over-expressed in ASCs of lactating mammary glands
and ASCs of cancers (CAFs). However, the upstream
regulator of its expression in normal and pathological
conditions is unclear. During embryonic development,
the crabp1 promoter is demethylated to induce gene ex-
pression in specific tissues [56], while in adult tissues,
the promoter becomes inaccessible through chromatin
modification to restrict its expression [57]. Crabp1 can
be activated by thyroid hormone (T3/T4) binding of the
holo-thyroid hormone receptors/retinoid receptors that
in turn bind to the thyroid response element (TRE) lo-
cated approximately 1 kb upstream of the crabp1 basal
promoter. The recruitment of this complex to the
crabp1 promoter results in disassembly of the nucleo-
some covering the transcription initiation site, chromatin
remodeling and histone acetylation which leads to a stable
state of active gene expression [46]. T3 is required for lac-
tation and its levels are the highest during this stage of de-
velopment [58,59]. Likewise, T3 levels have been reported
to be elevated in the serum of breast cancer patients
[60,61]. Thus, T3 may be a key regulator of crabp1 ex-
pression in the mammary adipose stroma (Figure 6G).
Indeed, the metastable phenotype of ASCs could be
observed even after removal of the cells from tissues
indicating that the mechanism regulating crabp1 ex-
pression is likely epigenetic. Further studies will be
needed to fully elucidate the mechanism regulating
crabp1 expression and whether thyroid hormone dir-
ectly modulates its expression in vivo.
(See figure on previous page.)
Figure 6 Crabp1 regulates CAF phenotype. (A) Tumor growth curve of mice injected at eight weeks of age with SUM159 cells co-mixed with
CAF-L cells (n = 10 per group). P value indicates significance compared to SUM159 cells alone. Data are means ± SEM. (B) Quantitative RT-PCR of
crabp1 in CAF-L cells transduced with shRNA for crabp1 or scrambled control. Data are presented as average 2(−ΔΔCt ± SEM; n = 3. (C) Representative
image of Oil Red O staining and quantification of CAF-L cells transduced with shRNA for crabp1 or scrambled control and exposed to adipocyte differ-
entiation media. Data are presented as average absorbance ± SEM. Untreated cell absorbance is set to one; n = 3 experiments. Scale bar = 100 μm.
(D) Representative image of Oil Red O staining and quantification of NIH3T3 cells treated with shRNA for crabp1 or scrambled control and
exposed to adipocyte differentiation media. Data are presented as average absorbance ± SEM. Untreated cell absorbance is set to one; n = 3
experiments. Scale bar = 100 μm. (E) Tumor growth curve of mice injected at eight weeks of age with SUM159 cells co-mixed with CAF-L cells
transduced with shRNA for crapb1 or scrambled control (n = 10 per group). P value indicates significance compared to shScr-CAF-L cells. Data
are means ± SEM. (F) Representative H & E images of SUM159 tumors co-mixed with CAF-L cells. V = vessel; MG =mammary gland duct. Scale
bar = 100 μm. (G) Representative images and quantification of the percentage of centralized tumor necrosis in SUM159 cells co-mixed with
CAF-L cells transduced with shRNA for crapb1 or scrambled control (n = 5 per group). (H) Schematic of phenotypic modulation of adipocytes
under physiologic (normal development) and pathologic (breast cancer progression) conditions. CAF-L, carcinoma-associated fibroblast-like;
crabp1, cellular retinoic acid binding protein-1; SEM, standard error of the mean.
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Conclusions
These findings imply that PABC is a complex disease
and, in agreement with clinical data, suggest that the lac-
tating microenvironment promotes aggressive tumors.
Both systemic and local factors are important for the
pathobiology of PABCs, and stromal changes during lac-
tation play a distinct and critical role in the progression
of PABCs that differ from those during post-lactational
involution. In addition, these findings reveal a previously
unrecognized and critical role of specialized adipose
stromal cells during lactation that contributes to PABC
pathobiology.
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Data are presented as means ± SEM. (C) Quantitative RT-PCR of VEGF-C,
PDGFc, and PlGF in adipose stromal cells isolated from nulliparous,
regressed and lactating mammary glands. Data are presented as average
2(−ΔCt) ± SEM; n = 3 experiments.
Additional file 13: Table S8. Description of data: Genes included in
Carcinoma Associated Fibroblast gene set used for GSEA analysis.
Additional file 14: Table S9. Description of data: Genes included in
Tumorigenesis gene set used for GSEA analysis.
Additional file 15: Table S10. Description of data: Genes included in
Breast Cancer Progression gene set used for GSEA analysis.
Additional file 16: Human breast cancers express crabp1.
Description of data: Enlarged images of immunofluorescence of human
mammary carcinoma either as xenografts in the HIM model (n = 4) or
primary human breast cancer tissues, n = 10. crapb1 (red) cytokeratin
(green) showing both positive (#2-3) or negative expression (neg).
Additional file 17: Table S11. Description of data: Clinical characteristics
of human breast cancer samples.
Additional file 18: Table S12. Description of data: Clinical characteristics
of human fibroblast samples.
Additional file 19: NIH3T3 cells express high levels of crabp1 protein.
Description of data: Western blot of crabp1in adipocytes isolated from the
fourth inguinal mammary gland.
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